Change: offered +7% / raised +230% / placed 100%
XDATA – August 22nd 2014
Tosk closed its unregistered equity offering after increasing the placement’s size by 7% to $5.45 million. The offer closed after the company raised $3.8 million from sixty-two additional investors within a little over a year. At closing, a total of seventy-four investors had subscribed to Tosk‘s offering. The company closed two unregistered private placements which raised an estimated $7 million.
Tosk develops drugs for debilitating and life-threatening diseases such as cancer, arthritis, and psoriasis. The company’s current drug discovery and development efforts focus on applying the optimizing market drug (OMD) technology to discover cancer chemotherapeutic side-effect-reducing agents.
The company, headquartered in Mountain View CA, is led by Brian Frenzel (President and CEO). Revenues on or below $1 million were reported by Tosk.
The board of directors includes Charles Garvin and Harold Crow.
The company has raised an estimated total of $12.45 million via private unregistered security offerings.
Amount offered: $5.45 million
Amount placed: $5.45 million
First sale: 12-16-2011
Data as of: 08-22-2014